Understanding the Risks of Investing in Outlook Therapeutics Inc (OTLK)
Outlook Therapeutics Inc’s filing revealed that its Director Haddadin Yezan Munther acquired Company’s shares for reported $22242.0 on Mar 28 ’24. In the deal valued at $11.82 per share,1,882 shares were bought. As a result of this transaction, Haddadin Yezan Munther now holds 5,049 shares worth roughly $46753.74. Then, Evanson Jeff bought 62,484 shares, generating […]